Rare Target Detection using Digital PCR
Digital PCR is ideally suited to detect and quantify rare targets
Rare target quantification in liquid biopsy
Specifically, identification and tracking of cancer-causing mutations via liquid biopsy can be used for early detection, measuring therapeutic response, quantifying residual tumor burden, and monitoring emerging resistance to targeted therapies. Here, we demonstrate compatibility with Applied Biosystems™ TaqMan™ Liquid Biopsy assays, performing robust detection of 5 different hotspot mutations down to 0.1% allelic frequency. See the TaqMan protocol here.
Precision cancer monitoring
Sensitive and precise detection of treatment-relevant cancer mutations with an existing 2-enzyme PCR chemistry
Differentiation of single nucleotide polymorphisms (SNPs) or single nucleotide variants (SNVs) using PCR can be challenging due to a myriad of factors including sequence specificity and the possibility of primer-dimer formation. In this application note, IDT’s rhAmp technology was used to design a point mutation detection assay for the hotspot cancer mutation EGFR p.T790M – detecting both the wild-type and mutation allele in a single digital PCR reaction.
Luminex & Absolute Q
Luminex uses the Combinati Absolute Q platform to identify underlying mechanisms of drug resistance in metastatic breast cancer with Luminex multiplex PCR chemistry.
Highlights of this webinar include:
- Introduction to Microfluidic Array Partitioning (MAP) technology for digital PCR
- Demonstration of a multiplex assay to identify and quantify 11 single nucleotide polymorphisms (SNPs) within the ESR1 gene in a single sample
- Utility of using the Absolute Q, a 4-color digital PCR platform with a walkaway workflow, in translational oncology research
Ready to learn more?
Find out more about harnessing the
power of Digital PCR for your research.